Arkolith/Insider Trading/SNDX/Form 4

Katkin Keith

DirectorSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed May 19, 2025
Net Buying
Open-Market Buys
$91K
Open-Market Sells
$0
Net Open-Market Flow
$91K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 19, 2025Buy(P)10K$9.11$91K100K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-074289) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML